{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:11:57Z","timestamp":1791403917844,"version":"4.3.3"},"reference-count":190,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre","doi-asserted-by":"publisher","award":["2019\/33\/B\/NZ5\/02510"],"award-info":[{"award-number":["2019\/33\/B\/NZ5\/02510"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Dedifferentiated chondrosarcoma (DDCS) is a rare subtype of chondrosarcoma, a primary cartilaginous malignant neoplasm. It accounts for up to 1\u20132% of all chondrosarcomas and is generally associated with one of the poorest prognoses among all chondrosarcomas with the highest risk of metastasis. The 5-year survival rates range from 7% to 24%. DDCS may develop at any age, but the average presentation age is over 50. The most common locations are the femur, pelvis humerus, scapula, rib, and tibia. The standard treatment for localised disease is surgical resection. Most patients are diagnosed in unresectable and advanced stages, and chemotherapy for localised and metastatic dedifferentiated DDCS follows protocols used for osteosarcoma.<\/jats:p>","DOI":"10.3390\/cancers15153924","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T10:57:33Z","timestamp":1690973853000},"page":"3924","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Dedifferentiated Chondrosarcoma from Molecular Pathology to Current Treatment and Clinical Trials"],"prefix":"10.3390","volume":"15","author":[{"given":"Weronika","family":"Zaj\u0105c","sequence":"first","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"},{"name":"Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Dr\u00f3\u017cd\u017c","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"},{"name":"Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Kisielewska","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"},{"name":"Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Karwowska","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"},{"name":"Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-4410","authenticated-orcid":false,"given":"Monika","family":"Dudzisz-\u015aled\u017a","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka E.","family":"Zaj\u0105c","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Borkowska","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Szumera-Cie\u0107kiewicz","sequence":"additional","affiliation":[{"name":"Department of Pathology, Maria Sklodowska Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7608-4800","authenticated-orcid":false,"given":"Bart\u0142omiej","family":"Szostakowski","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-5429","authenticated-orcid":false,"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-3810","authenticated-orcid":false,"given":"Anna M.","family":"Czarnecka","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00000478-199603000-00005","article-title":"Dedifferentiated chondrosarcoma with rhabdomyosarcomatous differentiation","volume":"20","author":"Reith","year":"1996","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_2","unstructured":"Wittig, J.C. (2023, February 20). Dedifferentiated Chondrosarcoma. Available online: https:\/\/tumorsurgery.org\/tumor-education\/bone-tumors\/types-of-bone-tumors\/dedifferentiated-chondrosarcoma.aspx?fbclid=IwAR08vgOA3CET_NS6UJaczgQK98xoKICoQKeFhBWD6VlXo6XKZgPGdxj_2XI."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2007-0237","article-title":"The clinical approach towards chondrosarcoma","volume":"13","author":"Gelderblom","year":"2008","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF00941235","article-title":"Dedifferentiated chondrosarcoma","volume":"24","author":"Mercuri","year":"1995","journal-title":"Skelet. Radiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/adpa.2002.33905","article-title":"Dedifferentiated chondrosarcoma with a noncartilaginous component mimicking a conventional giant cell tumor of bone","volume":"6","author":"Estrada","year":"2002","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/modpathol.2009.120","article-title":"Dedifferentiated peripheral chondrosarcomas: Regulation of EXT-downstream molecules and differentiation-related genes","volume":"22","author":"Rozeman","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"746909","DOI":"10.3389\/fmed.2021.746909","article-title":"Dedifferentiated Central Chondrosarcoma: A Clinical, Histopathological, and Immunohistochemical Analysis of 57 Cases","volume":"8","author":"Gong","year":"2021","journal-title":"Front. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jor.24463","article-title":"Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis","volume":"38","author":"Amer","year":"2020","journal-title":"J. Orthop. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"35448","DOI":"10.52965\/001c.35448","article-title":"Dedifferentiated Chondrosarcoma: A Case Series and Review of the Literature","volume":"14","author":"Gusho","year":"2022","journal-title":"Orthop. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.ejca.2007.06.016","article-title":"Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group","volume":"43","author":"Grimer","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.suronc.2018.05.009","article-title":"Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas","volume":"27","author":"Ho","year":"2018","journal-title":"Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.21037\/tcr-20-357","article-title":"Treatment method and prognostic factors of chondrosarcoma: Based on Surveillance, Epidemiology, and End Results (SEER) database","volume":"9","author":"Hua","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_13","unstructured":"Gaillard, F.J., and Kusel, K. (2023, February 20). Dedifferentiated Chondrosarcoma. Available online: https:\/\/radiopaedia.org\/articles\/6250."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00256-020-03651-1","article-title":"The incidence and diagnostic relevance of pathological fracture in conventional central chondrosarcoma","volume":"50","author":"Alqubaisi","year":"2021","journal-title":"Skelet. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.crad.2003.08.009","article-title":"Dedifferentiated chondrosarcoma: Use of MRI to guide needle biopsy","volume":"59","author":"Saifuddin","year":"2004","journal-title":"Clin. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9069272","DOI":"10.1155\/2019\/9069272","article-title":"Prognostic Factors in Dedifferentiated Chondrosarcoma: A Retrospective Analysis of a Large Series Treated at a Single Institution","volume":"2019","author":"Miao","year":"2019","journal-title":"Sarcoma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jso.24650","article-title":"Dedifferentiated chondrosarcoma: A survival analysis of 159 cases from the SEER database (2001\u20132011)","volume":"116","author":"Strotman","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Liu, C., Xi, Y., Li, M., Jiao, Q., Zhang, H., Yang, Q., and Yao, W. (2017). Dedifferentiated chondrosarcoma: Radiological features, prognostic factors and survival statistics in 23 patients. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0173665"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1749-799X-7-38","article-title":"Clinical outcome for patients with dedifferentiated chondrosarcoma: A report of 9 cases at a single institute","volume":"7","author":"Yokota","year":"2012","journal-title":"J. Orthop. Surg. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/cncr.21936","article-title":"Dedifferentiated central chondrosarcoma","volume":"106","author":"Staals","year":"2006","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/1097-0142(19860715)58:2<278::AID-CNCR2820580213>3.0.CO;2-6","article-title":"Chondrosarcoma with additional mesenchymal component (dedifferentiated chondrosarcoma). I. A clinicopathologic study of 26 cases","volume":"58","author":"Johnson","year":"1986","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ajmg.a.61530","article-title":"Natural history of Ollier disease and Maffucci syndrome: Patient survey and review of clinical literature","volume":"182","author":"Robbins","year":"2020","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2106\/00004623-198769020-00016","article-title":"The malignant potential of enchondromatosis","volume":"69","author":"Schwartz","year":"1987","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.aott.2018.10.008","article-title":"Coexistence of secondary chondrosarcoma and lung carcinoma metastasis in the humerus of a patient with Ollier\u2019s disease: A case report","volume":"53","author":"Aycan","year":"2019","journal-title":"Acta Orthop. Traumatol. Turc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100456","DOI":"10.1016\/j.jbo.2022.100456","article-title":"Appendicular dedifferentiated chondrosarcoma: A management and survival study from the SEER database","volume":"37","author":"Gonzalez","year":"2022","journal-title":"J. Bone Oncol."},{"key":"ref_26","first-page":"e29105","article-title":"A Case Report and Brief Literature Review on Dedifferentiated Chondrosarcoma in Proximal Phalanx: A Rare Location","volume":"14","author":"Desai","year":"2022","journal-title":"Cureus"},{"key":"ref_27","unstructured":"Graham, T.M. (2019, April 11). IHeartPathology Dedifferentiated Chondrosarcoma. Available online: https:\/\/www.iheartpathology.net\/."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/14737159.2.5.461","article-title":"Diagnosis and prognosis of chondrosarcoma of bone","volume":"2","author":"Rozeman","year":"2002","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"820254","DOI":"10.1155\/2012\/820254","article-title":"Putative multifunctional signature of lung metastases in dedifferentiated chondrosarcoma","volume":"2012","author":"Malchenko","year":"2012","journal-title":"Sarcoma"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10136","DOI":"10.12659\/MSM.919184","article-title":"Risk Factors for Incidence and Prognosis in Chondrosarcoma Patients with Pulmonary Metastasis at Initial Diagnosis","volume":"25","author":"Nguyen","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100069","DOI":"10.1016\/j.modpat.2022.100069","article-title":"Prognostic Significance of Percentage and Size of Dedifferentiation in Dedifferentiated Chondrosarcoma","volume":"36","author":"Hung","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s12262-012-0439-2","article-title":"Primary chondrosarcoma of male breast: A rare case","volume":"74","author":"Badyal","year":"2012","journal-title":"Indian J. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00264-015-2706-x","article-title":"Management and prognostic significance of pathological fractures through chondrosarcoma of the femur","volume":"39","author":"Albergo","year":"2015","journal-title":"Int. Orthop."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/0218492314522253","article-title":"Dedifferentiated chondrosarcoma: An aggressive variant of chondrosarcoma","volume":"23","author":"Bharath","year":"2015","journal-title":"Asian Cardiovasc. Thorac. Ann."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00256-012-1521-3","article-title":"The imaging of cartilaginous bone tumours. II. Chondrosarcoma","volume":"42","author":"Douis","year":"2012","journal-title":"Skelet. Radiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1148\/rg.245045009","article-title":"Radiographic, CT, and MR Imaging Features of Dedifferentiated Chondrosarcomas: A Retrospective Review of 174 De Novo Cases","volume":"24","author":"Littrell","year":"2004","journal-title":"RadioGraphics"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kim, J.-H., and Lee, S.K. (2023). Classification of Chondrosarcoma: From Characteristic to Challenging Imaging Findings. Cancers, 15.","DOI":"10.3390\/cancers15061703"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00256-003-0706-1","article-title":"Dedifferentiated chondrosarcoma of the appendicular skeleton: MRI-pathological correlation","volume":"32","author":"MacSweeney","year":"2003","journal-title":"Skelet. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Tlemsani, C., Larousserie, F., De Percin, S., Audard, V., Hadjadj, D., Chen, J., Biau, D., Anract, P., Terris, B., and Goldwasser, F. (2023). Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021361"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Gazendam, A., Popovic, S., Parasu, N., and Ghert, M. (2023). Chondrosarcoma: A Clinical Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072506"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1302\/0301-620X.82B1.0820050","article-title":"Ultrasound-guided needle biopsy of primary bone tumours","volume":"82","author":"Saifuddin","year":"2000","journal-title":"J. Bone Jt. Surg. Br."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-319-07323-1_6","article-title":"Chondrosarcoma of bone","volume":"162","author":"Leddy","year":"2014","journal-title":"Cancer Treat. Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Andreas F Mavrogenis, P.J.P. (2012, January 03). Bone: Dedifferentiated Chondrosarcoma. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available online: https:\/\/atlasgeneticsoncology.org\/solid-tumor\/5063\/bone-chondrosarcoma.","DOI":"10.4267\/2042\/47497"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1148\/radiol.2233011050","article-title":"Diagnosis of primary bone tumors with image-guided percutaneous biopsy: Experience with 110 tumors","volume":"223","author":"Jelinek","year":"2002","journal-title":"Radiology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1445-2197.2005.03332.x","article-title":"Accuracy of computed tomography guided core needle biopsy of musculoskeletal tumours","volume":"75","author":"Altuntas","year":"2005","journal-title":"ANZ J. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2214\/AJR.10.6145","article-title":"Revisiting CT-guided percutaneous core needle biopsy of musculoskeletal lesions: Contributors to biopsy success","volume":"197","author":"Omura","year":"2011","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jos.2020.12.017","article-title":"Image-guided core needle biopsy for musculoskeletal lesions","volume":"27","author":"Toki","year":"2022","journal-title":"J. Orthop. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2214\/ajr.171.3.ajronline_171_3_001","article-title":"Accuracy of CT-guided needle biopsy of musculoskeletal neoplasms","volume":"171","author":"Dupuy","year":"1998","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jjco\/hyy157","article-title":"New TNM classification (AJCC eighth edition) of bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group","volume":"49","author":"Tanaka","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4103\/0019-5413.132506","article-title":"The molecular pathogenesis of dedifferentiated chondrosarcoma","volume":"48","author":"Sakamoto","year":"2014","journal-title":"Indian. J. Orthop."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1078\/0344-0338-00443","article-title":"Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma","volume":"199","author":"Ropke","year":"2003","journal-title":"Pathol. Res. Pr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1440-1827.2010.02530.x","article-title":"Matrix biochemistry and cell biology of dedifferentiated chondrosarcomas","volume":"60","author":"Dornauer","year":"2010","journal-title":"Pathol. Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0344-0338(80)80218-4","article-title":"Malignant fibrous histiocytoma: Histological patterns and cell types","volume":"168","author":"Meister","year":"1980","journal-title":"Pathol. Res. Pr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/gcc.21974","article-title":"Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma","volume":"51","author":"Meijer","year":"2012","journal-title":"Genes. Chromosom. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3892\/ijmm_00000249","article-title":"A novel mutated cell line with characteristics of dedifferentiated chondrosarcoma","volume":"24","author":"Yang","year":"2009","journal-title":"Int. J. Mol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1111\/cas.15382","article-title":"Clinical features and treatment outcomes of dedifferentiated and grade 3 chondrosarcoma: A multi-institutional study","volume":"113","author":"Kozawa","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e1265716","DOI":"10.1080\/2162402X.2016.1265716","article-title":"Description of the immune microenvironment of chondrosarcoma and contribution to progression","volume":"6","author":"Simard","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"991724","DOI":"10.3389\/fonc.2022.991724","article-title":"Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response","volume":"12","author":"Singh","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/path.1027","article-title":"The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies","volume":"196","author":"Bingle","year":"2002","journal-title":"J. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Kim, J.R., Moon, Y.J., Kwon, K.S., Bae, J.S., Wagle, S., Kim, K.M., Park, H.S., Lee, H., Moon, W.S., and Chung, M.J. (2013). Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0082870"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.humpath.2014.11.001","article-title":"Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment","volume":"46","author":"Shoushtari","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2016.108","article-title":"Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype","volume":"29","author":"Kostine","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/PAI.0b013e318244ff4b","article-title":"Sox10 and S100 in the diagnosis of soft-tissue neoplasms","volume":"20","author":"Karamchandani","year":"2012","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrc3893","article-title":"S100 proteins in cancer","volume":"15","author":"Bresnick","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.mpdhp.2014.03.001","article-title":"Histologic variants of chondrosarcoma","volume":"20","author":"Chebib","year":"2014","journal-title":"Diagn. Histopath."},{"key":"ref_68","first-page":"149","article-title":"TP53 in bone and soft tissue sarcomas","volume":"202","author":"Thoenen","year":"2019","journal-title":"Pharmacology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00019606-199802000-00009","article-title":"p53 mutations in chondrosarcoma","volume":"7","author":"Terek","year":"1998","journal-title":"Diagn. Mol. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/modpathol.2014.155","article-title":"NY-ESO-1 (CTAG1B) expression in mesenchymal tumors","volume":"28","author":"Endo","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2012.31","article-title":"NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: Significance for NY-ESO-1-based targeted therapy and differential diagnosis","volume":"25","author":"Lai","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: Molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1126\/science.1170944","article-title":"Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha","volume":"324","author":"Zhao","year":"2009","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Macarulla","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.humpath.2018.09.015","article-title":"IDH mutation status in a series of 88 head and neck chondrosarcomas: Different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract","volume":"84","author":"Tallegas","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1200\/JCO.19.02492","article-title":"Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients with Advanced Chondrosarcoma","volume":"38","author":"Tap","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J. Pathol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.humpath.2017.05.015","article-title":"Diagnostic utility of IDH1\/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone","volume":"65","author":"Chen","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"100293","DOI":"10.1016\/j.jbo.2020.100293","article-title":"Clonality analysis and IDH1 and IDH2 mutation detection in both components of dedifferentiated chondrosarcoma, implicated its monoclonal origin","volume":"22","author":"Yang","year":"2020","journal-title":"J. Bone Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1158\/2767-9764.CRC-22-0397","article-title":"Distinct IDH1\/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma","volume":"3","author":"Dermawan","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcb.24940","article-title":"The epigenetic regulation of SOX9 by miR-145 in human chondrosarcoma","volume":"116","author":"Mak","year":"2015","journal-title":"J. Cell. Biochem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/CEJ.0b013e32833d942f","article-title":"Different expression of Sox9 and Runx2 between chondrosarcoma and dedifferentiated chondrosarcoma cell line","volume":"19","author":"Tang","year":"2010","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s004280050478","article-title":"Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma","volume":"436","author":"Grote","year":"2000","journal-title":"Virchows Arch."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/1097-0142(19950715)76:2<223::AID-CNCR2820760210>3.0.CO;2-4","article-title":"p53 expression in dedifferentiated chondrosarcoma","volume":"76","author":"Simms","year":"1995","journal-title":"Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.prp.2013.12.003","article-title":"Dedifferentiated chondrosarcoma mimicking a giant cell tumor. Is this low grade dedifferentiated chondrosarcoma?","volume":"210","author":"Knosel","year":"2014","journal-title":"Pathol. Res. Pr."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/(SICI)1096-9896(199912)189:4<454::AID-PATH467>3.0.CO;2-N","article-title":"Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis","volume":"189","author":"Bovee","year":"1999","journal-title":"J. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Gilbert, A. (2023). Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions. Cancers, 15.","DOI":"10.3390\/cancers15071962"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ajpath.2012.12.036","article-title":"Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFbeta as potential targets","volume":"182","author":"Meijer","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00428-012-1206-2","article-title":"Dedifferentiated peripheral chondrosarcoma: A clinicopathologic, immunohistochemical, and molecular analysis of four cases","volume":"460","author":"Franchi","year":"2012","journal-title":"Virchows Arch."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41379-018-0140-5","article-title":"H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features","volume":"32","author":"Makise","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Zajac, A.E., Kopec, S., Szostakowski, B., Spalek, M.J., Fiedorowicz, M., Bylina, E., Filipowicz, P., Szumera-Cieckiewicz, A., Tysarowski, A., and Czarnecka, A.M. (2021). Chondrosarcoma-from Molecular Pathology to Novel Therapies. Cancers, 13.","DOI":"10.3390\/cancers13102390"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0046-8177(96)90341-X","article-title":"Chondrocytic cell differentiation in clear cell chondrosarcoma","volume":"27","author":"Aigner","year":"1996","journal-title":"Hum. Pathol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/modpathol.2008.144","article-title":"Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: A tissue microarray-based comparative analysis","volume":"21","author":"Oakley","year":"2008","journal-title":"Mod. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/jclinpath-2018-205071","article-title":"Biomarkers of chondrosarcoma","volume":"71","author":"Jeong","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1600-0463.2009.02461.x","article-title":"Markers aiding the diagnosis of chondroid tumors: An immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40","volume":"117","author":"Daugaard","year":"2009","journal-title":"APMIS"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"151660","DOI":"10.1016\/j.anndiagpath.2020.151660","article-title":"NKX3.1 a useful marker for mesenchymal chondrosarcoma: An immunohistochemical study","volume":"50","author":"Syed","year":"2021","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"405437","DOI":"10.1155\/2011\/405437","article-title":"Chondrosarcoma: With updates on molecular genetics","volume":"2011","author":"Kim","year":"2011","journal-title":"Sarcoma"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.humpath.2018.03.012","article-title":"Mesenchymal chondrosarcomas showing immunohistochemical evidence of rhabdomyoblastic differentiation: A potential diagnostic pitfall","volume":"77","author":"Folpe","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.anndiagpath.2009.09.003","article-title":"Immunoprofile of mesenchymal chondrosarcoma: Aberrant desmin and EMA expression, retention of INI1, and negative estrogen receptor in 22 female-predominant central nervous system and musculoskeletal cases","volume":"14","author":"Auerbach","year":"2010","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000325014","article-title":"Diagnosis of a dedifferentiated chondrosarcoma of the pelvis by fine needle aspiration. A case report","volume":"54","year":"2010","journal-title":"Acta Cytol."},{"key":"ref_102","first-page":"2","article-title":"Giant Cell Tumor of Bone\u2014An Overview","volume":"4","author":"Sobti","year":"2016","journal-title":"Arch. Bone Jt. Surg."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF00734510","article-title":"Dedifferentiated chondrosarcoma of bone. An immunohistochemical and lectin-histochemical study","volume":"411","author":"Wick","year":"1987","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5858\/2008-132-326-UTTIBI","article-title":"Undifferentiated tumor: True identity by immunohistochemistry","volume":"132","author":"Bahrami","year":"2008","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/PAS.0b013e31824230d0","article-title":"MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: Correlation with a dedifferentiated subtype","volume":"36","author":"Yoshida","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1368-8375(03)00017-4","article-title":"Clinicopathological and immunohistochemical analysis of twenty-five head and neck osteosarcomas","volume":"39","author":"Junior","year":"2003","journal-title":"Oral. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jcpa.2017.07.005","article-title":"Immunohistochemical Validation of Spontaneously Arising Canine Osteosarcoma as a Model for Human Osteosarcoma","volume":"157","author":"Gunn","year":"2017","journal-title":"J. Comp. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4103\/1947-2714.183013","article-title":"Coexistence of HER2, Ki67, and p53 in Osteosarcoma: A Strong Prognostic Factor","volume":"8","author":"Mardanpour","year":"2016","journal-title":"N. Am. J. Med. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1354\/vp.42-2-161","article-title":"Use of alkaline phosphatase staining to differentiate canine osteosarcoma from other vimentin-positive tumors","volume":"42","author":"Barger","year":"2005","journal-title":"Vet. Pathol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.clon.2009.07.016","article-title":"Pathology of soft tissue sarcomas","volume":"21","author":"Thway","year":"2009","journal-title":"Clin. Oncol. R. Coll. Radiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"104638","DOI":"10.18632\/oncotarget.20136","article-title":"Current diagnostics and treatment of fibrosarcoma -perspectives for future therapeutic targets and strategies","volume":"8","author":"Augsburger","year":"2017","journal-title":"Oncotarget"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/his.12282","article-title":"Fibrosarcoma: A review and update","volume":"64","author":"Folpe","year":"2014","journal-title":"Histopathology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/00000478-199509000-00001","article-title":"Sclerosing epithelioid fibrosarcoma. A variant of fibrosarcoma simulating carcinoma","volume":"19","author":"Kindblom","year":"1995","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1354\/vp.40-3-288","article-title":"Histology and immunohistochemistry of seven ferret vaccination-site fibrosarcomas","volume":"40","author":"Munday","year":"2003","journal-title":"Vet. Pathol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/00000478-200108000-00007","article-title":"Pleomorphic leiomyosarcoma: Clinicopathologic and immunohistochemical study with special emphasis on its distinction from ordinary leiomyosarcoma and malignant fibrous histiocytoma","volume":"25","author":"Oda","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/01.MP.0000056983.78547.77","article-title":"Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: A review of 25 cases initially diagnosed as malignant fibrous histiocytoma","volume":"16","author":"Coindre","year":"2003","journal-title":"Mod. Pathol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2559.1987.tb02642.x","article-title":"An immunohistochemical study of differentiation in malignant fibrous histiocytoma","volume":"11","author":"Lawson","year":"1987","journal-title":"Histopathology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.5858\/2008-132-1030-MFHBTP","article-title":"Malignant fibrous histiocytoma: Between the past and the present","volume":"132","author":"Igbokwe","year":"2008","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2559.2003.01639.x","article-title":"Immunohistochemistry in the diagnosis of soft tissue tumours","volume":"43","author":"Coindre","year":"2003","journal-title":"Histopathology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/15513815.2015.1042604","article-title":"The Role of Immunohistochemistry in Rhabdomyosarcoma Diagnosis Using Tissue Microarray Technology and a Xenograft Model","volume":"34","author":"Machado","year":"2015","journal-title":"Fetal Pediatr. Pathol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.2005.03.4934","article-title":"Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry","volume":"24","author":"Wachtel","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00428-006-0284-4","article-title":"Spindle cell rhabdomyosarcoma in adults: Clinicopathological and immunohistochemical analysis of seven new cases","volume":"449","author":"Mentzel","year":"2006","journal-title":"Virchows Arch."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1002\/cncr.24486","article-title":"Cluster analysis of immunohistochemical markers in leiomyosarcoma delineates specific anatomic and gender subgroups","volume":"115","author":"Carvalho","year":"2009","journal-title":"Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/PAS.0b013e318287779c","article-title":"Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: Immunohistochemical study of 68 cases with clinical follow-up","volume":"37","author":"Mills","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"998","DOI":"10.7150\/jca.22915","article-title":"IDH1\/2 Mutations Predict Shorter Survival in Chondrosarcoma","volume":"9","author":"Lugowska","year":"2018","journal-title":"J. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.jos.2021.07.024","article-title":"Prognostic impact of IDH mutations in chondrosarcoma","volume":"27","author":"Nakagawa","year":"2022","journal-title":"J. Orthop. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1002\/cam4.4019","article-title":"Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis","volume":"10","author":"Vuong","year":"2021","journal-title":"Cancer Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41419-022-04916-4","article-title":"Mice with Trp53 and Rb1 deficiency in chondrocytes spontaneously develop chondrosarcoma via overactivation of YAP signaling","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Venneker, S., Kruisselbrink, A.B., Baranski, Z., Palubeckaite, I., Briaire-de Bruijn, I.H., Oosting, J., French, P.J., Danen, E.H.J., and Bovee, J. (2020). Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma. Cancers, 12.","DOI":"10.3390\/cancers12123589"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"100430","DOI":"10.1016\/j.jbo.2022.100430","article-title":"Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma","volume":"34","author":"Nakagawa","year":"2022","journal-title":"J. Bone Oncol."},{"key":"ref_131","unstructured":"Bov\u00e9e, J.V.M.G., Bloem, J.L., Flanagan, A.M., Nielsen, G.P., and Yoshida, A. (2020). WHO Classification of Tumours: Soft Tissue and Bone Tumours, WHO. [5th ed.]."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-019-12525-7","article-title":"Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression","volume":"10","author":"Nicolle","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., and Tsuchiya, H. (2022). Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031096"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"595187","DOI":"10.3389\/fonc.2020.595187","article-title":"Mutant p53 in Cancer Progression and Targeted Therapies","volume":"10","author":"Zhu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.cco.0000129678.72521.e5","article-title":"Genetics of chondrosarcoma and related tumors","volume":"16","author":"Sandberg","year":"2004","journal-title":"Curr. Opin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.5858\/arpa.2020-0379-OA","article-title":"Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma","volume":"145","author":"Lucas","year":"2021","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2018.09.001","article-title":"Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets","volume":"131","author":"Nazeri","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2324::AID-CNCR12>3.0.CO;2-U","article-title":"Altered p53 is associated with aggressive behavior of chondrosarcoma","volume":"83","author":"Oshiro","year":"1998","journal-title":"Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/hmg\/4.10.1883","article-title":"Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers","volume":"4","author":"Suzuki","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/ng.2668","article-title":"Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma","volume":"45","author":"Tarpey","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00428-014-1685-4","article-title":"Isocitrate dehydrogenase 1 mutations (IDH1) and p16\/CDKN2A copy number change in conventional chondrosarcomas","volume":"466","author":"Amary","year":"2015","journal-title":"Virchows Arch."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.12688\/f1000research.15953.1","article-title":"Chondrosarcoma: Biology, genetics, and epigenetics","volume":"7","author":"Chow","year":"2018","journal-title":"F1000Research"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"43557","DOI":"10.18632\/oncotarget.9618","article-title":"Targeted next-generation sequencing of dedifferentiated chondrosarcoma in the skull base reveals combined TP53 and PTEN mutations with increased proliferation index, an implication for pathogenesis","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0165-4608(00)00335-6","article-title":"Chromosomal changes in a dedifferentiated chondrosarcoma: A case report and review of the literature","volume":"124","author":"Opheim","year":"2001","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.2217\/fon-2021-0830","article-title":"Dedifferentiated chondrosarcoma: Current standards of care","volume":"17","author":"Kattepur","year":"2021","journal-title":"Future Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.ejso.2018.05.033","article-title":"The role of surgical margins in chondrosarcoma","volume":"44","author":"Stevenson","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.otsr.2009.05.004","article-title":"Pelvic chondrosarcomas: Surgical treatment options","volume":"95","author":"Deloin","year":"2009","journal-title":"Orthop. Traumatol. Surg. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00432-004-0648-6","article-title":"Dedifferentiated chondrosarcoma\u2014A fatal disease","volume":"131","author":"Bruns","year":"2005","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jos.2020.04.013","article-title":"Pathological fracture does not affect prognosis in dedifferentiated chondrosarcoma of the limbs","volume":"26","author":"Sambri","year":"2021","journal-title":"J. Orthop. Sci."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Walter, S.G., Kn\u00f6ll, P., Eysel, P., Quaas, A., Gaisendrees, C., Ni\u00dfler, R., and Hieggelke, L. (2023). Molecular In-Depth Characterization of Chondrosarcoma for Current and Future Targeted Therapies. Cancers, 15.","DOI":"10.3390\/cancers15092556"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1102\/1470-7330.2003.0022","article-title":"Imaging of chondrosarcomas","volume":"4","author":"Ollivier","year":"2003","journal-title":"Cancer Imaging"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ijscr.2020.06.092","article-title":"Successful treatment of a dedifferentiated chondrosarcoma of the proximal humerus with a hemicortical articular surface sparing allograft: A case report","volume":"72","author":"Gomez","year":"2020","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/IOP.0000000000000168","article-title":"Radiation-induced dedifferentiated chondrosarcoma with orbital invasion","volume":"30","author":"Davies","year":"2014","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"440","DOI":"10.52312\/jdrs.2022.526","article-title":"Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature","volume":"33","author":"Coskun","year":"2022","journal-title":"Jt. Dis. Relat. Surg."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1159\/000509386","article-title":"Skull Base Chordomas and Chondrosarcomas","volume":"110","author":"Kremenevski","year":"2020","journal-title":"Neuroendocrinology"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1002\/1097-0142(19800601)45:11<2769::AID-CNCR2820451111>3.0.CO;2-X","article-title":"Radiotherapy of chondrosarcoma of bone","volume":"45","author":"Harwood","year":"1980","journal-title":"Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0167-8140(83)80014-0","article-title":"Results of radical radiation for chondrosarcoma of bone","volume":"1","author":"Krochak","year":"1983","journal-title":"Radiother. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13569-018-0110-1","article-title":"Dedifferentiated chondrosarcoma of the pelvis: Clinical outcomes and current treatment","volume":"8","author":"Lex","year":"2018","journal-title":"Clin. Sarcoma Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.2106\/00004623-200411000-00008","article-title":"Dedifferentiated chondrosarcoma: The role of chemotherapy with updated outcomes","volume":"86","author":"Dickey","year":"2004","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/14737140.2019.1659731","article-title":"An update on current and future treatment options for chondrosarcoma","volume":"19","author":"MacDonald","year":"2019","journal-title":"Expert. Rev. Anticancer."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1634\/theoncologist.2017-0574","article-title":"Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma","volume":"24","author":"Conley","year":"2019","journal-title":"Oncologist"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Bui, N., Dietz, H., Farag, S., Hirbe, A.C., Wagner, M.J., Van Tine, B.A., Ganjoo, K., Jones, R.L., Keedy, V.L., and Davis, E.J. (2023). A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma. Cancers, 15.","DOI":"10.3390\/cancers15092617"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2106\/00004623-198668080-00008","article-title":"Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases","volume":"68","author":"Frassica","year":"1986","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/(SICI)1097-0142(19960815)78:4<745::AID-CNCR9>3.0.CO;2-D","article-title":"Chondrosarcoma of the pelvis. Prognostic factors for 67 patients treated with definitive surgery","volume":"78","author":"Sheth","year":"1996","journal-title":"Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s11999-013-3360-5","article-title":"Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma?","volume":"472","author":"Kawaguchi","year":"2014","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2021.04.017","article-title":"Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study","volume":"151","author":"Hompland","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/annonc\/mdt374","article-title":"Advanced chondrosarcomas: Role of chemotherapy and survival","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/CORR.0000000000002011","article-title":"Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database Analysis","volume":"480","author":"Cranmer","year":"2022","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1302\/0301-620X.82B1.0820055","article-title":"Experience in the treatment of dedifferentiated chondrosarcoma","volume":"82","author":"Mitchell","year":"2000","journal-title":"J. Bone Jt. Surg. Br."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1302\/0301-620X.94B1.26876","article-title":"The treatment of locally recurrent chondrosarcoma: Is extensive further surgery justified?","volume":"94","author":"Streitbuerger","year":"2012","journal-title":"J. Bone Jt. Surg. Br."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"100271","DOI":"10.1016\/j.jbo.2019.100271","article-title":"The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target","volume":"20","author":"Iseulys","year":"2020","journal-title":"J. Bone Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"30093","DOI":"10.1038\/srep30093","article-title":"Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma","volume":"6","author":"Koirala","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40425-018-0413-z","article-title":"Response to PD1 inhibition in conventional chondrosarcoma","volume":"6","author":"Wagner","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13569-016-0064-0","article-title":"Response to anti-PD1 therapy with nivolumab in metastatic sarcomas","volume":"6","author":"Paoluzzi","year":"2016","journal-title":"Clin. Sarcoma Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"11522","DOI":"10.1200\/JCO.2020.38.15_suppl.11522","article-title":"IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I\/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort","volume":"38","author":"Palmerini","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1158\/1078-0432.CCR-12-3647","article-title":"Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon-2016-0226","article-title":"Novel therapeutic approaches in chondrosarcoma","volume":"13","author":"Polychronidou","year":"2017","journal-title":"Future Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1158\/0008-5472.CAN-08-4801","article-title":"Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment","volume":"69","author":"Schrage","year":"2009","journal-title":"Cancer Res."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-012-1968-x","article-title":"Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas","volume":"70","author":"Kollender","year":"2012","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"772263","DOI":"10.3389\/fonc.2021.772263","article-title":"Metabolic Pathways and Targets in Chondrosarcoma","volume":"11","author":"Micaily","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/cncr.25632","article-title":"A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-alpha or -beta: An Italian Sarcoma Group study","volume":"117","author":"Grignani","year":"2011","journal-title":"Cancer"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.30379","article-title":"Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor","volume":"123","author":"Schuetze","year":"2017","journal-title":"Cancer"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Albarran, V., Villamayor, M.L., Chamorro, J., Rosero, D.I., Pozas, J., San Roman, M., Calvo, J.C., Perez de Aguado, P., Moreno, J., and Guerrero, P. (2022). Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213784"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"982424","DOI":"10.3389\/fphar.2022.982424","article-title":"Recent advances of IDH1 mutant inhibitor in cancer therapy","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/annonc\/mdt391","article-title":"GDC-0449 in patients with advanced chondrosarcomas: A French Sarcoma Group\/US and French National Cancer Institute Single-Arm Phase II Collaborative Study","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e79432","DOI":"10.7554\/eLife.79432","article-title":"EZH2\/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression","volume":"12","author":"Lin","year":"2023","journal-title":"Elife"},{"key":"ref_187","unstructured":"M.D. Anderson Cancer Center (2023, July 27). LN-145 or LN-145-S1 in Treating Patients with Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03449108."},{"key":"ref_188","first-page":"16","article-title":"187TiP Phase II, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144\/LN-145\/LN-145-S1) in patients with solid tumours","volume":"04","author":"Gettinger","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"155","DOI":"10.6004\/jnccn.2017.0017","article-title":"NCCN Guidelines Insights: Bone Cancer, Version 2.2017","volume":"15","author":"Biermann","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: A non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3924\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:24:08Z","timestamp":1760127848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":190,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15153924"],"URL":"https:\/\/doi.org\/10.3390\/cancers15153924","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}